
Annual report 2024
added 12-27-2025
Trinity Biotech plc Revenue 2011-2025 | TRIB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Trinity Biotech plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.6 M | 56.8 M | 62.5 M | 81.1 M | 102 M | 90.4 M | 97 M | 99.1 M | 99.6 M | 100 M | 105 M | 91.2 M | 82.5 M | 77.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 56.8 M | 86.2 M |
Quarterly Revenue Trinity Biotech plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 M | - | - | - | 25.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.4 M | 25 M | 25.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
41 M | $ 19.33 | 0.21 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
508 M | $ 20.97 | -1.38 % | $ 226 M | ||
|
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
6.81 M | $ 0.23 | -4.4 % | $ 6.75 M | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
332 M | $ 39.53 | -1.4 % | $ 1.1 B | ||
|
BioNano Genomics
BNGO
|
30.8 M | $ 1.52 | - | $ 1.93 M | ||
|
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.17 | 1.29 % | $ 289 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
3.62 B | $ 67.51 | 0.13 % | $ 26.1 B | ||
|
Danaher Corporation
DHR
|
23.9 B | $ 230.0 | -0.45 % | $ 168 B | ||
|
Exact Sciences Corporation
EXAS
|
2.76 B | $ 101.56 | 0.02 % | $ 18.8 B | ||
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
283 M | $ 26.78 | -0.85 % | $ 810 M | ||
|
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
280 M | $ 19.47 | -1.32 % | $ 1.05 B | ||
|
Anixa Biosciences
ANIX
|
210 K | $ 3.21 | -6.25 % | $ 102 K | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
15.4 B | $ 226.52 | 0.26 % | $ 41.1 B | ||
|
Guardant Health
GH
|
739 M | $ 103.35 | 0.94 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
838 M | $ 6.44 | -1.68 % | $ 583 M | ||
|
Illumina
ILMN
|
4.37 B | $ 135.12 | -0.15 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
4.05 B | $ 203.88 | - | $ 10.5 B | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.94 | -3.14 % | $ 2.65 M | ||
|
Neogen Corporation
NEOG
|
895 M | $ 7.12 | -0.35 % | $ 1.54 B | ||
|
National Research Corporation
NRC
|
149 M | $ 18.74 | 0.46 % | $ 460 M | ||
|
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 176.16 | 0.15 % | $ 19.6 B | ||
|
Biodesix
BDSX
|
71.3 M | $ 6.76 | -0.88 % | $ 877 M | ||
|
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
13 B | $ 254.32 | 0.02 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
5.48 B | $ 182.75 | -0.51 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
3.9 B | $ 688.22 | 0.01 % | $ 56.8 B | ||
|
Pacific Biosciences of California
PACB
|
201 M | $ 1.77 | -5.85 % | $ 449 M | ||
|
Lantheus Holdings
LNTH
|
1.53 B | $ 66.73 | 0.07 % | $ 4.62 B | ||
|
Mettler-Toledo International
MTD
|
3.87 B | $ 1 419.64 | 0.11 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
6.32 B | $ 138.31 | 0.03 % | $ 42 B | ||
|
Biomerica
BMRA
|
5.31 M | $ 2.7 | 1.9 % | $ 6.2 M | ||
|
Bioventus
BVS
|
512 M | $ 7.4 | 0.27 % | $ 464 M | ||
|
NeoGenomics
NEO
|
661 M | $ 12.33 | 0.2 % | $ 1.56 B |